Researchers compared patient-reported outcome measures, expert panel assessment, and computerized outcomes tool to determine which method was the gold standard for aesthetic outcomes of surgical treatment for breast cancer.

Women with meningioma have a 10-fold higher risk of developing breast cancer than women in the general population, a meta-analysis suggests.

Common barriers to screening adherence include race/ethnicity, low socioeconomic and education levels.

Nurse response to remote symptom monitoring (RSM) system alert may not be influenced by severity of patient’s symptoms or cancer stage.

A large observational cohort study in England showed improvements in 5-year breast cancer mortality rates for women with early breast cancer.

Clinically important differences seen in prevalence of dense breasts even after adjustment for body mass index.

Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.

Sacituzumab govitecan improves outcomes vs physician’s choice of treatment in patients with endocrine-resistant, HR+, HER2- metastatic breast cancer, results from the phase 3 TROPiCS-02 study suggest.

Findings seen in patients with hormone receptor-positive advanced breast cancer with relapse, progression during aromatase inhibitor treatment.

Patients with HR+, HER2- metastatic breast cancer whose disease progressed on endocrine therapy (ET) and a CDK4/6 inhibitor have better progression-free survival if they switch ET and receive ribociclib than if they switch ET alone, a phase 2 study suggests.